Sphere Fluidics Launches Cyto-Mine Chroma
Sphere Fluidics, a prominent provider of cutting-edge microfluidics solutions, recently announced the launch of its latest innovation, Cyto-Mine Chroma. This exciting development marks a significant advancement for the Cyto-Mine single-cell analysis platform, tailored for functional analysis and isolation. The announcement, made during a key conference, emphasizes the company’s commitment to enhancing research capabilities across various fields, including antibody discovery and cell therapy.
Overview of Cyto-Mine Chroma
Cyto-Mine Chroma is designed to revolutionize single-cell analysis, offering enhanced capabilities such as multiplexing and increased assay flexibility. This next-gen platform enables researchers to conduct extensive screening, analyzing tens of millions of cells in a single day. With the integration of a four-color laser and detector system, the platform allows for the analysis of numerous parameters for each cell in one assay, setting a new standard for efficiency and precision in the field.
Early Access Program
The launch includes an Early Access Program, opening opportunities for select customers to demo Cyto-Mine Chroma before its broader release. This initiative aims to accelerate project timelines and improve outcomes by collaborating with innovative clients who can provide valuable feedback, thus shaping future applications and assays on the platform.
Benefits of Cyto-Mine Chroma
This pioneering technology supports the development of the company’s first multiplexed assay kit, enabling various readouts within a single experiment. By optimizing throughput and precision in cell selection, Cyto-Mine Chroma can significantly reduce project timelines from months down to weeks, while also minimizing costs and labor effort.
Showcasing Innovations
Sphere Fluidics will feature Cyto-Mine Chroma at their booth during a major international conference. The Chief Technology Officer will be presenting a detailed spotlight on the platform's capabilities, demonstrating how it can transform research methodologies in lab automation and screening.
Comments from CEO Dale Levitzke
CEO Dale Levitzke expressed enthusiasm about the launch, commenting, "The next-generation Cyto-Mine Chroma platform is designed to provide transformative insights into single-cell analysis. Unveiling this innovative platform at the premier event for lab automation and screening showcases our dedication to pushing the boundaries of biotechnology. Our collaboration with key industry players will drive the evolution of our microfluidic technologies to meet current and future needs in the sector."
Moving Forward
As Sphere Fluidics continues to innovate, the introduction of Cyto-Mine Chroma represents an important step in their mission to advance single-cell analysis technologies. The combination of advanced capabilities and support for early collaborators positions the platform as a game-changer in biotechnological research and development.
Frequently Asked Questions
What is Cyto-Mine Chroma?
Cyto-Mine Chroma is a next-generation single-cell analysis platform designed to enhance efficiency and precision in cell screening.
What applications does Cyto-Mine Chroma support?
The platform supports various applications, including antibody discovery, cell line development, and cell therapy.
How does the Early Access Program work?
The Early Access Program allows select customers to demo the platform, providing feedback that will shape its future applications.
What benefits does Cyto-Mine Chroma offer?
It offers multiplexing capabilities, faster project timelines, reduced costs, and improved selection of candidate cells.
Where can I learn more about Cyto-Mine Chroma?
For more information, interested parties can visit the Sphere Fluidics website and explore the details related to Cyto-Mine Chroma.
